Kerala Ayurveda Ltd has approved the issuance of 4,000 Series ‘A’ Non-Convertible Debentures (NCDs) totaling ₹400 million. The move is aimed at strengthening the company’s financial base, supporting expansion plans, and enhancing liquidity to meet growing demand in India’s wellness and Ayurveda sector.
The issuance reflects Kerala Ayurveda’s strategy to leverage debt instruments for long-term growth while maintaining financial discipline. With rising interest in Ayurveda-based healthcare, the company is positioning itself to capture market opportunities through enhanced funding.
Issuance Details
The board has approved 4,000 Series ‘A’ NCDs, aggregating to ₹400 million. These instruments are expected to provide stable returns to investors while ensuring capital availability for the company’s operational and strategic initiatives.
Strategic Importance
The NCD issuance underscores Kerala Ayurveda’s commitment to scaling its business in the wellness and healthcare domain. It also highlights the company’s focus on balancing traditional Ayurvedic expertise with modern financial strategies to drive sustainable growth.
Industry Context
India’s Ayurveda and wellness industry is expanding rapidly, supported by government initiatives and rising consumer demand. Companies like Kerala Ayurveda are tapping into this momentum by strengthening their capital structures.
Key Highlights
* Kerala Ayurveda approves issuance of 4,000 Series ‘A’ NCDs
* Total value of issuance stands at ₹400 million
* Move supports expansion and liquidity needs
* Reflects growing investor interest in Ayurveda sector
* Aligns with India’s wellness industry growth trajectory
Sources: SEBI filings, Economic Times, Business Standard